NASDAQ:CRVO CervoMed (CRVO) Stock Price, News & Analysis $7.07 -0.01 (-0.14%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$7.00 -0.07 (-0.99%) As of 10/24/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CervoMed Stock (NASDAQ:CRVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CervoMed alerts:Sign Up Key Stats Today's Range$6.97▼$7.1650-Day Range$7.07▼$10.6952-Week Range$1.80▼$16.94Volume43,895 shsAverage Volume113,089 shsMarket Capitalization$65.42 millionP/E RatioN/ADividend YieldN/APrice Target$19.86Consensus RatingHold Company Overview CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts. Read More CervoMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreCRVO MarketRank™: CervoMed scored higher than 70% of companies evaluated by MarketBeat, and ranked 302nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingCervoMed has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 6 buy ratings, 1 hold rating, and 3 sell ratings.Upside PotentialCervoMed has a consensus price target of $19.86, representing about 180.9% upside from its current price of $7.07.Amount of Analyst CoverageCervoMed has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CervoMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CervoMed are expected to grow in the coming year, from ($1.88) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CervoMed is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CervoMed is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCervoMed has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CervoMed's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.03% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CervoMed has recently decreased by 5.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCervoMed does not currently pay a dividend.Dividend GrowthCervoMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.03% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CervoMed has recently decreased by 5.81%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.84 News SentimentCervoMed has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for CervoMed this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for CRVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CervoMed insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.15% of the stock of CervoMed is held by institutions.Read more about CervoMed's insider trading history. Receive CRVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CervoMed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRVO Stock News HeadlinesCervoMed Releases Investor Presentation on WebsiteOctober 22 at 4:50 PM | tipranks.comCervoMed to Present at the Emerging Growth ConferenceOctober 20, 2025 | markets.businessinsider.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.October 25 at 2:00 AM | Banyan Hill Publishing (Ad)CervoMed to Present at the Emerging Growth ConferenceOctober 20, 2025 | globenewswire.comCervoMed price target raised to $20 from $16 at Roth CapitalOctober 17, 2025 | msn.comCervoMed stock soars after positive dementia treatment trial dataOctober 9, 2025 | za.investing.comCervoMed shares jump after strong results in dementia drug trialOctober 9, 2025 | msn.comCervoMed Unveils Promising Phase 2b Trial ResultsOctober 9, 2025 | msn.comSee More Headlines CRVO Stock Analysis - Frequently Asked Questions How have CRVO shares performed this year? CervoMed's stock was trading at $2.34 at the beginning of the year. Since then, CRVO shares have increased by 202.1% and is now trading at $7.07. How were CervoMed's earnings last quarter? CervoMed Inc. (NASDAQ:CRVO) issued its earnings results on Friday, August, 8th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.13. The firm had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.45 million. CervoMed had a negative trailing twelve-month return on equity of 59.15% and a negative net margin of 290.72%. Who are CervoMed's major shareholders? CervoMed's top institutional investors include Citizens Financial Group Inc. RI (0.33%) and Perigon Wealth Management LLC (0.31%). How do I buy shares of CervoMed? Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CervoMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that CervoMed investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/08/2025Today10/25/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVO Previous SymbolNASDAQ:CRVO CIK1053691 Webdiffusionpharma.com Phone14342200718Fax434-220-0722Employees4Year FoundedN/APrice Target and Rating Average Price Target for CervoMed$19.86 High Price Target$31.00 Low Price Target$11.00 Potential Upside/Downside+180.9%Consensus RatingHold Rating Score (0-4)2.45 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.29 million Net Margins-290.72% Pretax Margin-290.72% Return on Equity-59.15% Return on Assets-53.64% Debt Debt-to-Equity RatioN/A Current Ratio8.20 Quick Ratio8.20 Sales & Book Value Annual Sales$9.74 million Price / Sales6.71 Cash FlowN/A Price / Cash FlowN/A Book Value$4.50 per share Price / Book1.57Miscellaneous Outstanding Shares9,250,000Free Float5,977,000Market Cap$65.40 million OptionableNot Optionable Beta-0.84 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CRVO) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.